Sasaki Hidefumi, Hikosaka Yu, Kawano Osamu, Yano Motoki, Fujii Yoshitaka
Department of Oncology, Immunology and Surgery, Nagoya City University Medical School, Nagoya 467-8601, Japan.
Oncol Lett. 2010 Mar;1(2):303-307. doi: 10.3892/ol_00000054. Epub 2010 Mar 1.
Large tumor suppressor (LATS) 1 and 2 are tumor suppressor genes implicated in the regulation of the cell cycle. The methylation statuses of the promoter regions of these genes were studied in Japanese lung cancers. The methylation statuses of the promoter regions of LATS1 and LATS2 were investigated by methylation-specific PCR. The findings were compared to clinicopathological features of lung cancer. Methylation-specific PCR showed that the LATS1 promoter region was hypermethylated in 95 out of 119 (79.8%) lung cancers. The methylation status of LATS1 was significantly associated with squamous histology (p=0.0267) and smoking status (never smoker vs. smoker; p=0.0399). LATS1-ummethylated patients harbored more EGFR mutations (p=0.0143). The LATS2 promoter region was hypermethylated in 160 out of 203 (78.8%) lung cancers. However, the methylation status had no association with the clinicopathological characteristics of the lung cancers cases. Both the LATS1 and LATS2 methylation statuses did not correlate with survival of lung cancer patients. Thus, the EGFR methylation status of the LATS genes has limited value in Japanese lung cancers.
大肿瘤抑制因子（LATS）1和2是参与细胞周期调控的肿瘤抑制基因。在日本肺癌患者中研究了这些基因启动子区域的甲基化状态。采用甲基化特异性PCR检测LATS1和LATS2启动子区域的甲基化状态，并将结果与肺癌的临床病理特征进行比较。甲基化特异性PCR结果显示，119例肺癌中有95例（79.8%）LATS1启动子区域发生高甲基化。LATS1的甲基化状态与鳞状组织学（p=0.0267）和吸烟状态（从不吸烟者与吸烟者；p=0.0399）显著相关。LATS1未甲基化的患者携带更多的表皮生长因子受体（EGFR）突变（p=0.0143）。203例肺癌中有160例（78.8%）LATS2启动子区域发生高甲基化。然而，甲基化状态与肺癌病例的临床病理特征无关。LATS1和LATS2的甲基化状态均与肺癌患者的生存率无关。因此，LATS基因的EGFR甲基化状态在日本肺癌中的价值有限。
